Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Silexion Therapeutics Corp SLXN

Healthcare Biotechnology
Silexion Therapeutics Corp is an oncology-focused biotechnology company. The Company is engaged in the development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of... see more

Recent & Breaking News (NDAQ:SLXN)

    Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

    GlobeNewswire 2 days ago

    Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

    Business Wire October 1, 2024

    Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER(TM) in Non-Resectable Pancreatic Cancer

    Business Wire September 24, 2024

    PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

    Business Wire September 9, 2024

    Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

    GlobeNewswire September 3, 2024